|
产品描述： Atracurium (BW-33A) besylate is a potent, competitive and non-depolarizing neuromuscular blocking agent. Atracurium besylate also is an AChR receptor antagonist. Atracurium besylate induces bronchoconstriction and neuromuscular blockade. Atracurium besylate promotes astroglial differentiation |
|
靶点：
Atracurium besylate (10 µM; 72 h) promotes astroglial but not neuronal differentiation in HSR040622 and HSR040821 cells. Atracurium besylate (10 µM; 48 h) reduces tumor engraftment and increases survival of mice xenotransplanted with ex-vivo treated GSCs. Atracurium besylate (2.4 µM; 120 min) induces a complete fade of the tetanic contraction while only slightly affected the twitch in rat extensor digitorum longus muscle cells;AChR |
参考文献：
1. Basta SJ, et al. Clinical pharmacology of atracurium besylate (BW 33A): a new non-depolarizing muscle relaxant. Anesth Analg. 1982 Sep;61(9):723-9. 2. Levitt RC, et al. Genetic susceptibility to atracurium-induced bronchoconstriction. Am J Respir Crit Care Med. 1995 May;151(5):1537-42. 3. Mayer B, et al. Inflammatory liver disease shortens atracurium-induced neuromuscular blockade in rats. Eur J Anaesthesiol. 2001 Sep;18(9):599-604. 4. Spina R, et al. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells. Oncotarget. 2016 Jan 5;7(1):459-72. 5. Nascimento DC, et al. Cellular mechanisms of atracurium-induced tetanic fade in the isolated rat muscle. Basic Clin Pharmacol Toxicol. 2004 Jul;95(1):9-14. |
|
溶解性：
Soluble in DMSO、H2O |
|
保存条件：
2-8℃ |
配置溶液浓度参考：
|
1mg |
5mg |
10mg |
| 1 mM |
0.804 ml |
4.021 ml |
8.042 ml |
| 5 mM |
0.161 ml |
0.804 ml |
1.608 ml |
| 10 mM |
0.08 ml |
0.402 ml |
0.804 ml |
| 50 mM |
0.016 ml |
0.08 ml |
0.161 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京